Brain Imaging Drug Use Prevention Messages (R21)

The summary for the Brain Imaging Drug Use Prevention Messages (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Brain Imaging Drug Use Prevention Messages (R21): Purpose. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate exploratory, i.e., descriptive, hypothesis-generating, research on neurobiological responses to substance abuse prevention media messages in humans using established brain imaging methods. There is particular interest in studies across developmental stages and age groups. Research supported under this FOA may eventually be used to develop a new generation of effective, tailored anti-drug messages. Given the relative lack of empirical research in this area, this initiative expects proposals to be exploratory, hypothesis-generating studies rather than confirmatory studies. Since applications are to be exploratory in nature, pilot data that provide support for the proposed hypotheses and aims (i.e., Proof of Concept) are not required, nor should applications be penalized for lacking preliminary data supporting the proposed hypotheses and aims. However, applicants are encouraged to provide evidence that they have the capability to conduct the studies (i.e. Proof of Feasibility), by documenting the availability of needed resources, the training and experience of the investigator team, and/or the conduct of related studies.

Federal Grant Title:	Brain Imaging Drug Use Prevention Messages (R21)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health Education
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DA-07-007
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Drug Abuse and Addiction Research Programs
Current Application Deadline:	No deadline provided
Original Application Deadline:	Mar 16, 2007
Posted Date:	Nov 17, 2006
Creation Date:	Nov 17, 2006
Archive Date:	Apr 15, 2007
Total Program Funding:	$3,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Special district governments Others (see text field entitled "Additional Information on Eligibility" for clarification) Native American tribal organizations (other than Federally recognized tribal governments) Small businesses Native American tribal governments (Federally recognized) County governments Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Public housing authorities/Indian housing authorities For profit organizations other than small businesses Private institutions of higher education
Additional Information on Eligibility: Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply. General Characteristics of Responsive Applications In order to be judged responsive, applications submitted under this FOA must 1) be conducted in human subjects, but not necessarily in subjects who are current or past users of drugs of abuse; 2) use either established substance abuse prevention media messages or public service announcements (PSAs) (a) whose effectiveness has been empirically investigated, (b) are based on a specific conceptual model or (c) has been in a current or past public media campaign; 3) use an established brain imaging method capable of detecting regional brain activity (e.g. fMRI, MRS, SPECT, PET, Source Localized Evoked Potentials) elicited in response to the presentation of prevention media messages. Applications that only use drug-related stimuli that are not part of a larger prevention message are not appropriate, but such material can be used as a comparison condition. Applications that solely employ methods that do not measure brain responses to presentation of the prevention message (e.g. structural MRI, Diffusion Tensor Imaging, Computed Tomography) or where brain activation is inferred (e.g. cognitive or neuropsychological measures) are not appropriate, unless they are used in conjunction with functional brain imaging methods.. Applications that only incorporate physiological methods not tied to the activity of specific brain regions (e.g., non-localized EEG/ERP, peripheral psychophysiological measures) are not appropriate, but such measures can be used in conjunction with a regional brain imaging technique; 4) be conducted by multidisciplinary teams with cognitive neuroscience, brain imaging, prevention research and health communications expertise. Applicants are strongly encouraged to contact program staff with any questions regarding the responsiveness of their proposed project to the goals of this FOA. Applicants may submit more than one application, provided each application is scientifically distinct.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...; • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...; • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...; • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed); • NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required); • Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Olde...; • NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies w...; • Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental S...